Literature DB >> 16785460

Re-examining our approach to the approval and use of new drugs.

Shoo K Lee1.   

Abstract

Mesh：

Year:  2006        PMID： 16785460      PMCID： PMC1475894          DOI： 10.1503/cmaj.060581

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Postmarketing surveillance and adverse drug reactions: current perspectives and future needs.

Authors:  T Brewer; G A Colditz
Journal:  JAMA       Date:  1999-03-03       Impact factor: 56.272

2.  Timing of new black box warnings and withdrawals for prescription medications.

Authors:  Karen E Lasser; Paul D Allen; Steffie J Woolhandler; David U Himmelstein; Sidney M Wolfe; David H Bor
Journal:  JAMA       Date:  2002-05-01       Impact factor: 56.272

3.  Information sources and clinical decisions.

Authors:  J K Stross
Journal:  J Gen Intern Med       Date:  1987 May-Jun       Impact factor: 5.128

4.  The role of commercial sources in the adoption of a new drug.

Authors:  M Y Peay; E R Peay
Journal:  Soc Sci Med       Date:  1988       Impact factor: 4.634

5.  Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus.

Authors:  Carlo Bellini; Francesco Campone; Giovanni Serra
Journal:  CMAJ       Date:  2006-06-20       Impact factor: 8.262
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.